PI3K inhibitor C 96

• CAT Number: I034721
• CAS Number: 1502813-63-9
• Molecular Formula: C11H8N2O3S
• Molecular Weight: 248.25
• Purity: 98%
• Synonyms: PI3K inhibitor C 96; PI3K-IN-C96; PI3K IN C96
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: 5-[(E)-3-thiophen-2-ylprop-2-enylidene]-1,3-diazinane-2,4,6-trione
• InChI: InChI=1S/C11H8N2O3S/c14-9-8(10(15)13-11(16)12-9)5-1-3-7-4-2-6-17-7/h1-6H,(H2,12,13,14,15,16)/b3-1+
• InChIKey: XVDGTYMDHFXORY-HNQUOIGGSA-N
• SMILES: C1=CSC(=C1)/C=C/C=C2C(=O)NC(=O)NC2=O

PI3K inhibitor C 96（Cat No.:I034721）is a small-molecule compound designed to selectively inhibit the phosphoinositide 3-kinase (PI3K) signaling pathway, which plays a crucial role in regulating cell growth, survival, and metabolism. PI3K is often overactive in various cancers, contributing to tumor progression and resistance to therapy. C 96 targets and inhibits specific isoforms of PI3K, disrupting these cellular processes and potentially reducing tumor growth. This compound is primarily used in preclinical studies to evaluate its efficacy in treating PI3K-driven cancers, with potential applications in cancer therapy if proven safe and effective in clinical trials.

Reference

1: Naderi R, Esmaeili-Mahani S, Abbasnejad M. Phosphatidylinositol-3-kinase and protein kinase C are involved in the pro-cognitive and anti-anxiety effects of phytohormone abscisic acid in rats. Biomed Pharmacother. 2017 Dec;96:112-119. doi: 10.1016/j.biopha.2017.09.089. Epub 2017 Sep 29. PubMed PMID: 28968539.
2: Lim W, Bae H, Bazer FW, Song G. Stimulatory effects of fibroblast growth factor 2 on proliferation and migration of uterine luminal epithelial cells during early pregnancy. Biol Reprod. 2017 Jan 1;96(1):185-198. doi: 10.1095/biolreprod.116.142331. PubMed PMID: 28395342.
3: Previs RA, Armaiz-Pena GN, Ivan C, Dalton HJ, Rupaimoole R, Hansen JM, Lyons Y, Huang J, Haemmerle M, Wagner MJ, Gharpure KM, Nagaraja AS, Filant J, McGuire MH, Noh K, Dorniak PL, Linesch SL, Mangala LS, Pradeep S, Wu SY, Sood AK. Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies. J Natl Cancer Inst. 2017 Jul 1;109(7). doi: 10.1093/jnci/djw296. PubMed PMID: 28376174.
4: Gu SH, Hsieh YC, Lin PL. Signaling involved in PTTH-stimulated 4E-BP phosphorylation in prothoracic gland cells of Bombyx mori. J Insect Physiol. 2017 Jan;96:1-8. doi: 10.1016/j.jinsphys.2016.10.007. Epub 2016 Oct 14. PubMed PMID: 27751888.
5: Ding X, Faber K, Shi Y, McKnight J, Dorshorst D, Ware JA, Dean B. Validation and determination of taselisib, a β-sparing phosphoinositide 3-kinase (PI3K) inhibitor, in human plasma by LC-MS/MS. J Pharm Biomed Anal. 2016 Jul 15;126:117-23. doi: 10.1016/j.jpba.2016.04.030. Epub 2016 Apr 20. PubMed PMID: 27187764.
6: Baik SH, Lee J, Lee YS, Jang JY, Kim CW. ANT2 shRNA downregulates miR-19a and miR-96 through the PI3K/Akt pathway and suppresses tumor growth in hepatocellular carcinoma cells. Exp Mol Med. 2016 Mar 25;48:e222. doi: 10.1038/emm.2015.126. PubMed PMID: 27012708; PubMed Central PMCID: PMC4892878.
7: Liu W, Liu B, Liu S, Zhang J, Lin S. Sphingosine-1-phosphate receptor 2 mediates endothelial cells dysfunction by PI3K-Akt pathway under high glucose condition. Eur J Pharmacol. 2016 Apr 5;776:19-25. doi: 10.1016/j.ejphar.2016.02.056. Epub 2016 Feb 26. PubMed PMID: 26921757.
8: Jang JY, Kim YG, Nam SJ, Keam B, Kim TM, Jeon YK, Kim CW. Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer. Mol Cancer Ther. 2016 Jun;15(6):1387-96. doi: 10.1158/1535-7163.MCT-15-0089. Epub 2016 Feb 16. PubMed PMID: 26883272.
9: Xie W, Wang H, Liu Q, Li Y, Wang J, Yao S, Wu Q. ResolvinD1 reduces apoptosis and inflammation in primary human alveolar epithelial type 2 cells. Lab Invest. 2016 May;96(5):526-36. doi: 10.1038/labinvest.2016.31. Epub 2016 Feb 15. PubMed PMID: 26878131.
10: Wang L, Yin J, Wang X, Shao M, Duan F, Wu W, Peng P, Jin J, Tang Y, Ruan Y, Sun Y, Gu J. C-Type Lectin-Like Receptor 2 Suppresses AKT Signaling and Invasive Activities of Gastric Cancer Cells by Blocking Expression of Phosphoinositide 3-Kinase Subunits. Gastroenterology. 2016 May;150(5):1183-1195.e16. doi: 10.1053/j.gastro.2016.01.034. Epub 2016 Feb 6. PubMed PMID: 26855187.
11: Costa C, Pereira S, Lima L, Peixoto A, Fernandes E, Neves D, Neves M, Gaiteiro C, Tavares A, Gil da Costa RM, Cruz R, Amaro T, Oliveira PA, Ferreira JA, Santos LL. Abnormal Protein Glycosylation and Activated PI3K/Akt/mTOR Pathway: Role in Bladder Cancer Prognosis and Targeted Therapeutics. PLoS One. 2015 Nov 16;10(11):e0141253. doi: 10.1371/journal.pone.0141253. eCollection 2015. PubMed PMID: 26569621; PubMed Central PMCID: PMC4646664.
12: De Giusti VC, Orlowski A, Ciancio MC, Espejo MS, Gonano LA, Caldiz CI, Vila Petroff MG, Villa-Abrille MC, Aiello EA. Aldosterone stimulates the cardiac sodium/bicarbonate cotransporter via activation of the g protein-coupled receptor gpr30. J Mol Cell Cardiol. 2015 Dec;89(Pt B):260-7. doi: 10.1016/j.yjmcc.2015.10.024. Epub 2015 Oct 21. PubMed PMID: 26497404.
13: Qu F, Xia B, Li X, Guo S, Zhang L, Tian C, Yu Y, Zhang Y. [Effects of the phosphoinostitide-3′-kinase delta inhibitor, CAL-101, in combination with Bortezomib on mantle lymophma cells and exploration of its related mechanism]. Zhonghua Zhong Liu Za Zhi. 2015 Jun;37(6):412-7. Chinese. PubMed PMID: 26463142.
14: Xing XS, Liu F, He ZY. Akt regulates β-catenin in a rat model of focal cerebral ischemia-reperfusion injury. Mol Med Rep. 2015 Apr;11(4):3122-8. doi: 10.3892/mmr.2014.3000. Epub 2014 Nov 26. PubMed PMID: 25435199.
15: Ding X, Li F, McKnight J, Schmidt C, Strooisma K, Shimizu H, Faber K, Ware JA, Dean B. A supported liquid extraction-LC-MS/MS method for determination of GDC-0980 (Apitolisib), a dual small-molecule inhibitor of class 1A phosphoinositide 3-kinase and mammalian target of rapamycin, in human plasma. J Pharm Biomed Anal. 2014 Nov;100:150-156. doi: 10.1016/j.jpba.2014.08.001. Epub 2014 Aug 10. PubMed PMID: 25165011.
16: Dai Y, Li F, Wu L, Wang R, Li P, Yan S, Xu H, Xia M, Bai C. Roxithromycin treatment inhibits TGF-β1-induced activation of ERK and AKT and down-regulation of caveolin-1 in rat airway smooth muscle cells. Respir Res. 2014 Aug 11;15:96. doi: 10.1186/s12931-014-0096-z. PubMed PMID: 25109503; PubMed Central PMCID: PMC4256937.
17: Wilson JM, Kunnimalaiyaan S, Gamblin TC, Kunnimalaiyaan M. MK2206 inhibits hepatocellular carcinoma cellular proliferation via induction of apoptosis and cell cycle arrest. J Surg Res. 2014 Oct;191(2):280-5. doi: 10.1016/j.jss.2014.05.083. Epub 2014 Jun 4. PubMed PMID: 24996256.
18: Mahajan-Thakur S, Sostmann BD, Fender AC, Behrendt D, Felix SB, Schrör K, Rauch BH. Sphingosine-1-phosphate induces thrombin receptor PAR-4 expression to enhance cell migration and COX-2 formation in human monocytes. J Leukoc Biol. 2014 Oct;96(4):611-8. doi: 10.1189/jlb.3AB1013-567R. Epub 2014 Jul 2. PubMed PMID: 24990321.
19: Shao T, Wang J, Chen JG, Wang XM, Li H, Li YP, Li Y, Yang GD, Mei QB, Zhang SQ. Discovery of 2-methoxy-3-phenylsulfonamino-5-(quinazolin-6-yl or quinolin-6-yl)benzamides as novel PI3K inhibitors and anticancer agents by bioisostere. Eur J Med Chem. 2014 Mar 21;75:96-105. doi: 10.1016/j.ejmech.2014.01.053. Epub 2014 Jan 29. PubMed PMID: 24530495.
20: Kukkonen JP. Lipid signaling cascades of orexin/hypocretin receptors. Biochimie. 2014 Jan;96:158-65. doi: 10.1016/j.biochi.2013.06.015. Epub 2013 Jun 28. Review. PubMed PMID: 23810911.